Zenas BioPharma: BLA Filed, Stock Crushed, Valuation Absorbing Too Much Fear

Zenas BioPharma submitted its BLA to the FDA on May 28. That was supposed to be the moment investors had been waiting months for - the formal ask for approval of obexelimab in IgG4-RD. Instead the stock fell roughly 20% on the news. From its 52-week high of $44.54, ZBIO now sits around $18.40, down nearly 60%. The market is punishing a company that just completed its most important milestone.

I'm taking a contrarian stance here. The panic selling has pushed the enterprise value to $710 million after the company raised $300 million in equity and added a $250 million debt facility earlier this year. That dilution pain is real. But the valuation reset has moved faster than the business fundamentals deteriorated. The INDIGO data hasn't changed. The approval probability hasn't changed. The investor base has.